問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Cardiovascular Diseases

Division of Rheumatology

Division of General Internal Medicine

更新時間：2023-09-19

陳瑋昇Chen, Wei-Sheng
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳瑋昇

Taipei Veterans General Hospital

Division of Rheumatology

List

33Cases

2016-12-01 - 2021-03-22

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2015-09-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2017-04-01 - 2019-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

2016-06-06 - 2022-03-10

Phase III

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    ABT-494

Participate Sites
8Sites

Terminated7Sites

黃春明
China Medical University Hospital-Taipei

未分科

2015-05-01 - 2017-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2011-10-01 - 2012-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2012-11-01 - 2014-11-01

Phase II

A Randomized, Double-Blind, Placebo-Controlled Trial of AC-201 In Subjects with Gout Initiating Urate-Lowering Therapy

  • Condition/Disease

    Gout

  • Test Drug

    AC-201

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

2014-11-03 - 2016-11-01

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF AC 201 IN SUBJECTS WITH GOUT

  • Condition/Disease

    Osteoarthritis

  • Test Drug

    AC-201

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

黃春明
China Medical University Hospital

Division of Rheumatology

2012-10-02 - 2015-12-31

Phase III

A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

2016-09-30 - 2019-12-31

Phase II

A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis

  • Condition/Disease

    Active psoriatic arthritis

  • Test Drug

    BI655066

Participate Sites
9Sites

Terminated7Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

黃春明
China Medical University Hospital-Taipei

未分科

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB